🧫
FK866 in azoxymethane/DSS colitis-associated cancer model
active
experiment
Created: 2026-04-10T14:44:04
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-383c7be4-05e7-4bfc-90d8-fb74be80ae90
🧫 Experiment Protocol
ValidationColitis-associated cancerNAMPTAOM/DSS-treated miceproposed
Evaluation of FK866's therapeutic potential in preventing inflammation-associated tumorigenesis using the azoxymethane (AOM)/DSS model of colitis-associated cancer in mice. This experiment assessed whether NAMPT inhibition could suppress both inflammatory processes and tumor development in the context of chronic intestinal inflammation. The study demonstrated that FK866 treatment effectively suppressed inflammation-associated tumorigenesis, indicating that NAD metabolism plays a crucial role not only in acute inflammation but also in the progression from chronic inflammation to cancer.
PRIMARY OUTCOME
Tumor development and inflammatory markers
EXPECTED OUTCOMES
Reduced tumor formation and suppressed inflammatory tumorigenesis
SUCCESS CRITERIA
Decreased tumor incidence and size, reduced inflammatory markers
PROTOCOL
Sequential AOM and DSS treatment to induce colitis-associated cancer followed by FK866 intervention with assessment of tumor formation and inflammatory parameters
LINKED HYPOTHESES
Source: PMID 28877980 ↗
🧫 Experiment Extras
PATHWAY
NAD salvage pathway, inflammation-cancer axis
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.